Physician profile
William Jacob Aronson
NPI 1639194095
$539,552.19
in general payments reported to CMS, 2019-2025
26 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $71K · 2021: $56K · 2022: $69K · 2023: $84K · 2024: $84K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Travel and Lodging: $43K · Consulting Fee: $19K · Honoraria: $5,975 · Food and Beverage: $5,127 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,423.25 |
| Travel and Lodging | $43,421.83 |
| Consulting Fee | $19,161.58 |
| Honoraria | $5,975.00 |
| Food and Beverage | $5,126.85 |
| Education | $203.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $165,351.73 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $148,841.78 | 2019-2025 | |
| Janssen Biotech, INC. | $86,134.57 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Pfizer INC. | $85,871.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $10,543.22 | 2020-2025 | Lynparza, Imfinzi |
| Sumitomo Pharma America, INC. | $6,753.61 | 2023-2024 | Orgovyx |
| Blue Earth Diagnostics | $6,212.01 | 2023-2024 | |
| Astellas Pharma Global Development | $5,225.00 | 2024-2025 | Xtandi |
| Progenics Pharmaceuticals, INC. | $5,075.00 | 2020-2021 | |
| Amgen INC. | $5,039.05 | 2019-2021 | |
| Myovant Sciences INC. | $4,864.67 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $3,344.90 | 2024-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $3,045.82 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $1,300.00 | 2022 | |
| Dendreon Pharmaceuticals LLC | $861.34 | 2022-2025 | Provenge |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $316.47 | 2019 | |
| Boston Scientific Corporation | $226.38 | 2019-2025 | Ams 700, Tactra, Lithovue |
| Procept Biorobotics Corporation | $205.42 | 2023 | Aquabeam Robotic System |
| Astellas Pharma INC | $140.88 | 2024 | Xtandi |
| Abbvie INC. | $126.95 | 2022-2023 | Lupron Depot |
| Immunitybio, INC. | $29.93 | 2025 | |
| Photocure INC | $19.27 | 2025 | Cysview |
| Exelixis INC. | $14.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Aronson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.